Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 137173A

Next Previous
Drug Profile

GSK 137173A

Alternative Names: GSK 1437173A; GSK137173A; Herpes zoster vaccine candidate (Hz/su) - GSK; PED-HZ/su; QS-21 containing herpes zoster vaccine - GSK/Agenus; recombinant adjuvanted Herpes Zoster vaccine; Shingrix; Varicella zoster vaccine - GSK; Varicella zoster virus vaccine - GSK; VZV gE; VZV vaccine - GSK/Agenus

Latest Information Update: 29 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK; Japan Vaccine
  • Class Subunit vaccines; Synthetic vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster

Most Recent Events

  • 29 Jan 2026 Phase III development is ongoing in Herpes Zoster (Prevention) in Finland
  • 29 Jan 2026 No development reported - Phase-III for Herpes zoster in India (IM)
  • 07 Jan 2026 GSK plans to launch GSK 137173A in prefilled syringe presentation for Herpes zoster (Prevention) in the European Union in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top